

PE anti-human CD178 (Fas-L) Antibody

Catalog# / Size	306406 / 25 tests 306407 / 100 tests
Clone	NOK-1
Regulatory Status	RUO
Workshop	VII 70322
Other Names	Fas Ligand (FasL), CD95L, TNFSF6, Fas-L
Isotype	Mouse IgG1, κ
Description	CD178 is a 38-42 kD type II glycoprotein also known as Fas ligand and CD95L. CD178 belongs to the TNF superfamily and is expressed on activated T lymphocytes, NK cells, monocytes, and granulocytes. CD178 is also expressed on parenchymal cells of the retina and cornea, retinal pigment epithelial cells, and testis. The extracellular region of FasL can be cleaved by matrix metalloproteinases (MMPs) to give rise to a 26 kD soluble protein. CD178 binds to CD95, a member of the TNFR superfamily, to induce apoptosis. CD95/CD95L interactions play an important role in the maintenance of peripheral tolerance and survival.

Product Details

Verified Reactivity	Human
Reported Reactivity	Baboon
Antibody Type	Monoclonal
Host Species	Mouse
Immunogen	L5178Y mouse T lymphoma cells expressing recombinant human FasL
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation	The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration	Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
Excitation Laser	Blue Laser (488 nm) Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes	Additional reported applications (for the relevant formats) include: immunoprecipitation ^{1,2} , immunofluorescence microscopy ³ , immunocytochemistry ² , blocking of Fas induced apoptosis ¹ , and Western blotting ¹¹ . Fas Ligand is expressed at low density on activated cells. For most successful immunofluorescent staining results, it may be important to maximize signal over background by using a relatively bright fluorochrome-antibody conjugate (Cat. No. 306407) or by using a high sensitivity, three-layer staining technique (e.g., including a biotinylated antibody (Cat. No. 306404) or biotinylated anti-mouse IgG second step (Cat. No. 405303), followed by SAV-PE (Cat. No. 405204)). In addition, applying matrix metalloproteinases (MMPS) inhibitor in the cell culture system will increase the FasL staining intensity. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 306415 and 306416).
Application References	

1. Kayagaki N, *et al.* 1995. *J. Exp. Med.* 182:1777.
2. Herr I, *et al.* 2000. *Cell Death Differ.* 7:129. (WB)
3. Bossi G, *et al.* 1999. *Nature Medicine* 5:90.
4. Andreola G, *et al.* 2002. *J. Exp. Med.* 195:1303.
5. Strauss L, *et al.* 2009. *J. Immunol.* 182:1469. [PubMed](#)
6. Li JH, *et al.* 2009. *Am J. Pathol.* 175:1124. [PubMed](#)
7. Zhao Q, *et al.* 2011. *Fitoterapia.* 82:735. [PubMed](#)
8. Kruger K, *et al.* 2011. *J. Appl. Physiol.* 110:1226. [PubMed](#)
9. Qin G, *et al.* 2012. *J. Infect. Dis.* [PubMed](#)
10. Khalid M, *et al.* 2012. *J. Virol.* 86:4906. [PubMed](#)
11. Qin G, *et al.* 2012. *J. Infect. Dis.* 205:1646. [PubMed](#)
12. Shrestha B, *et al.* 2012. *J. Virol.* 86:8937. [PubMed](#)
13. Mooren FC, *et al.* 2012. *J. Appl. Physiol.* 113:1082. [PubMed](#)
14. Robinet P, *et al.* 2014. *J Immunol.* 192:5332. [PubMed](#)
15. Wang Y, *et al.* 2014. *J Endocrinol.* 222:151. [PubMed](#)

Product Citations

1. Wang Y, *et al.* 2014. *J Endocrinol.* 222:151. [PubMed](#)
2. Sulejmani O, *et al.* 2021. *Cancers (Basel).* 13:. [PubMed](#)
3. Afolabi LO, *et al.* 2021. *Front Immunol.* 12:701671. [PubMed](#)
4. Beatson RE, *et al.* 2021. *Cell Rep Med.* 2:100473. [PubMed](#)
5. Fujii C, *et al.* 2016. *Sci Rep.* 6:35314. [PubMed](#)
6. Contreras-Ochoa CO, *et al.* 2022. *Iran J Basic Med Sci.* 25:383. [PubMed](#)
7. Hofmann L, *et al.* 2022. *Front Med (Lausanne).* 9:904295. [PubMed](#)
8. Medina M, *et al.* 2012. *J Leukoc Biol.* 91:759. [PubMed](#)
9. Felices M, *et al.* 2018. *JCI Insight.* 3. [PubMed](#)
10. Wu J, *et al.* 2021. *Adv Sci (Weinh).* 8:e2101029. [PubMed](#)
11. Van der Meer JMR, *et al.* 2021. *Oncoimmunology.* 10:1981049. [PubMed](#)
12. Zhao Q, *et al.* 2011. *Fitoterapia.* 82:735. [PubMed](#)
13. Meng Q, *et al.* 2021. *J Immunother Cancer.* 9:. [PubMed](#)
14. Meggyes M, *et al.* 2021. *Biomolecules.* 11:. [PubMed](#)
15. Robinet P, *et al.* 2014. *J Immunol.* 192:5332. [PubMed](#)
16. Lamichhane R *et al.* 2019. *Cell Rep.* 28(12):3061-3076 . [PubMed](#)
17. Schönberger S, *et al.* 2020. *Cancers (Basel).* 12:. [PubMed](#)
18. Carrion B, *et al.* 2021. *Neurol Neuroimmunol Neuroinflamm.* 8:. [PubMed](#)
19. Lake CM, *et al.* 2021. *Cell Death Dis.* 12:400. [PubMed](#)

RRID

AB_314603 (BioLegend Cat. No. 306406)
 AB_2100664 (BioLegend Cat. No. 306407)

Antigen Details

Structure	TNF superfamily, type II glycoprotein, 38-42 kD, 26 kD soluble form
Distribution	Activated T cells, NK cells, testis, eye, neutrophils, Clara type II cells
Function	Apoptosis, immune privilege
Ligand/Receptor	CD95
Cell Type	Neutrophils, NK cells, T cells
Biology Area	Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Immunology, Neuroscience
Molecular Family	CD Molecules
Antigen References	<ol style="list-style-type: none"> 1. Suda T, <i>et al.</i> 1997. <i>J. Exp. Med.</i> 12:204. 2. Kayagaki N, <i>et al.</i> 1995. <i>J. Exp. Med.</i> 182:1777. 3. Tanaka M, <i>et al.</i> 1995. <i>EMBO J.</i> 14:1129.
Gene ID	356


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

Biotin anti-human CD178 (Fas-L), PE anti-human CD178 (Fas-L), Purified anti-human CD178 (Fas-L), Brilliant Violet 421™ anti-human CD178 (Fas-L), TotalSeq™-A0177 anti-human CD178 (Fas-L), Ultra-LEAF™ Purified anti-human CD178 (Fas-L), PE/Cyanine7 anti-human CD178 (Fas-L), TotalSeq™-C0177 anti-human CD178 (Fas-L) Antibody, APC anti-human CD178 (Fas-L)

Product Data



Human Fas Ligand transfected cells
stained with NOK-1 PE

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587